Abcam, ab309839-100µL, Alexa Fluor® 488 Anti-CHD4 antibody [EPR12229]

Product details
How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on recombinant antibodies.
Patented technology Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
CHD4 acts within the NuRD complex to mediate transcriptional repression. This complex combines chromatin remodeling with histone deacetylation to alter chromatin dynamics affecting gene expression. CHD4's involvement in the complex facilitates the static organization of chromatin therefore contributing to transcriptional silencing of specific gene sets. The protein's activity is often in response to environmental and developmental cues playing an integral role in cellular differentiation and proliferation processes.
Pathways
CHD4 connects closely with DNA damage repair and cell cycle regulation pathways. It participates actively in the DNA damage response pathway by facilitating the repair of double-strand breaks working alongside proteins such as ATM and ATR. CHD4 also influences the cell cycle by interacting with cyclins and cyclin-dependent kinases which maintain proper cell cycle progression and check points.